43
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          CD4(+) T cells that express the forkhead box P3 (FOXP3) transcription factor function as regulatory T (Treg) cells and hinder effective immune responses against cancer cells. Abundant Treg cell infiltration into tumors is associated with poor clinical outcomes in various types of cancers. However, the role of Treg cells is controversial in colorectal cancers (CRCs), in which FOXP3(+) T cell infiltration indicated better prognosis in some studies. Here we show that CRCs, which are commonly infiltrated by suppression-competent FOXP3(hi) Treg cells, can be classified into two types by the degree of additional infiltration of FOXP3(lo) nonsuppressive T cells. The latter, which are distinguished from FOXP3(+) Treg cells by non-expression of the naive T cell marker CD45RA and instability of FOXP3, secreted inflammatory cytokines. Indeed, CRCs with abundant infiltration of FOXP3(lo) T cells showed significantly better prognosis than those with predominantly FOXP3(hi) Treg cell infiltration. Development of such inflammatory FOXP3(lo) non-Treg cells may depend on secretion of interleukin (IL)-12 and transforming growth factor (TGF)-β by tissues and their presence was correlated with tumor invasion by intestinal bacteria, especially Fusobacterium nucleatum. Thus, functionally distinct subpopulations of tumor-infiltrating FOXP3(+) T cells contribute in opposing ways to determining CRC prognosis. Depletion of FOXP3(hi) Treg cells from tumor tissues, which would augment antitumor immunity, could thus be used as an effective treatment strategy for CRCs and other cancers, whereas strategies that locally increase the population of FOXP3(lo) non-Treg cells could be used to suppress or prevent tumor formation.

          Related collections

          Author and article information

          Journal
          Nat. Med.
          Nature medicine
          1546-170X
          1078-8956
          Jun 2016
          : 22
          : 6
          Affiliations
          [1 ] Experimental Immunology, World Premier International Research Center (WPI), Immunology Frontier Research Center, Graduate School of Medicine, Osaka University, Osaka, Japan.
          [2 ] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
          [3 ] Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.
          [4 ] RIKEN Center for Integrative Medical Sciences (IMS), Kanagawa, Japan.
          [5 ] Department of Pathology, Institute of Medical Science (Medical Research Center), Tokyo Medical University, Tokyo, Japan.
          [6 ] Graduate School of Frontier Sciences, University of Tokyo, Chiba, Japan.
          [7 ] School of Veterinary Medicine, Azabu University, Kanagawa, Japan.
          Article
          nm.4086
          10.1038/nm.4086
          27111280
          13a40f79-29ee-4d36-867d-e6f2e2b0cf78
          History

          Comments

          Comment on this article